Valuation: Therapeutic Solutions International, Inc.

Market Cap 1.14M 995K 940K 853K 1.6M 109M 1.61M 11.25M 4.34M 55.67M 4.29M 4.19M 179M P/E 2022
-4.13x
P/E 2023 -1.46x
Enterprise Value 2M 1.75M 1.65M 1.5M 2.8M 192M 2.82M 19.74M 7.62M 97.63M 7.52M 7.35M 314M EV / Sales 2022
81.1x
EV / Sales 2023 47.1x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
24-11-20 Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-19 Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-30 Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-04-17 Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
24-04-16 Therapeutic Solutions International, Inc. Auditor Raises 'Going Concern' Doubt CI
24-03-04 Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients CI
23-12-11 Therapeutic Solutions International, Inc. Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease CI
23-11-14 Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-10-20 Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene CI
23-10-17 Res Nova Bio Appoints George Delgado to Scientific Advisory Board CI
23-09-29 Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils CI
23-09-18 Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board CI
23-08-21 Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Manager TitleAgeSince
Chief Executive Officer 68 2011-03-30
Chief Tech/Sci/R&D Officer 56 2019-09-02
Chief Tech/Sci/R&D Officer 61 2018-06-17
Director TitleAgeSince
Chairman 68 2012-01-02
Director/Board Member 51 2016-01-21
Change 5-day change 1-year change 3-year change Capi.($)
-1.37%-20.00% - - 7.05K
+0.11%+2.71%+0.33%+28.59% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%+0.67%+11.79%+40.51% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+8.12%+22.15%+38.93% 15.32B
-3.14%+31.91%-10.60% - 14.5B
Average -1.03%+4.59%+51.29%+120.69% 29.49B
Weighted average by Cap. -1.03%+2.74%+65.68%+131.93%

Financials

2022 2023
Net sales 207K 180K 170K 155K 290K 19.84M 291K 2.04M 787K 10.09M 777K 759K 32.46M 98.99K 86.32K 81.51K 74.02K 139K 9.5M 139K 976K 377K 4.83M 372K 364K 15.54M
Net income -3.68M -3.21M -3.03M -2.75M -5.15M -353M -5.17M -36.27M -14M -179M -13.82M -13.51M -577M -2.17M -1.89M -1.79M -1.62M -3.04M -208M -3.05M -21.4M -8.26M -106M -8.15M -7.97M -341M
Net Debt 1.06M 924K 872K 792K 1.48M 102M 1.49M 10.45M 4.03M 51.69M 3.98M 3.89M 166M 860K 750K 708K 643K 1.21M 82.54M 1.21M 8.48M 3.27M 41.97M 3.23M 3.16M 135M
Logo Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!